BerGenBio

Norway
Bergen, Vestland, Norway, 5009

Company profile

BerGenBio company profile

BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2007-01-01, Year

Headquarters

Postal code
5009
Country code
NO
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
10
Total equity funding
$150.7M
Last funding
Post IPO Debt / $23.1M / 2023-11-30
Last equity funding
Post IPO Equity / $48.8M
Investors
4
Lead investors
3
Founders
2
Articles
101
Exited on
2017-04-06

Founders and investors

Founders

David MicklemJames Lorens

Lead investors

InvestinorMeteva ASSarsia Seed Management

Investors

Birk VentureInvestinorMeteva ASSarsia Seed Management